At a glance
- Originator Esperion Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Diabetes mellitus; Low HDL cholesterol
Most Recent Events
- 29 Apr 2002 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
- 29 Apr 2002 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
- 29 Apr 2002 Discontinued - Preclinical for Low HDL cholesterol in USA (unspecified route)